PTO/SB/21 (05-03)

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

A 200		Application Numbe	r	10/648,811
TRANSMITT	AL	Filing Date		August 25, 2003
FORM	First Named Invent	or	Paul A. Price	
्रा भूकि be used for all correspondence afte	Group Art Unit		Unassigned	
		Examiner Name		Unassigned
Total Number of Pages in This Submi	ssion	Attorney Docket Nun	nber	407T-895413US
	ENCLOS	SURES (check all that	apply)	
Fee Transmittal Form		nent Papers Application)		After Allowance Communication to Group Appeal Communication to Board
Fee Attached	Drawing	(s)		of Appeals and Interferences
Amendment / Response	Licensir	ng-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition and Acc	Routing Slip (PTO/SB/69 companying Petition	9)	Proprietary Information
Affidavits/declaration(s)	1	to Convert to a nal Application		Status Letter
Extension of Time Request	f Attorney, Revocation of Correspondence	X	Additional Enclosure(s) (please identify below):	
Express Abandonment Request Addres		, Il Disclaimer		PTO Form 1449 receipt acknowledgment
s		ntity Statement		postcard
X Information Disclosure Statement		t for Refund		
Document(s) Please charge		o Charge Deposit Accou eposit Account No. 50-08	393 for a	ny additional fees associated with
		of the documents enclos		on, including any extensions of time
Response to Missing	Remarks			
Parts under 37 CFR 1.52 or 1.53				
SIGNATU	RE OF APPLI	CANT, ATTORNEY, (OR AGI	ENT
Firm or Individual name Tom Hunter, Re	eg. No. 38,498	, Quine Intel	llectual	Property Law Group P.C.
Signature Cam	Hung			
Date March 4, 2005				
		ATE OF MAILING		
I hereby certify that this correspondence is being facsimile to envelope addressed to: Commissioner for Patents, P.O. Box	ransmitted to the USPT x 1450, Alexandria, VA	O or deposited with the United State 22313-1450, DC 20231 on this date	es Postal Se e: March 4,	ervice with sufficient postage as first class mail in an 2005
Typed or printed name Phianti A	opling 7	_		
Signature	クカし		Date	3/4/05

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on March 4, 2005



QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Chianti Apolin

Attorney Docket No. 407T-895413US Client Ref. No. 92-206-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Paul A. Price, et al.

Application No.: 10/648,811

Filed: August 25, 2003

For: ASSAY FOR YKL-40 AS A

MARKER FOR DEGRADATION OF

MAMMALIAN CONNECTIVE

TISSUE MATRICES

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/215,077 (now U.S. Patent 6,794,150) filed December 18, 1998. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/215,077(now U.S. Patent 6,794,150) filed December 18, 1998 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Paul A. Price, et al.

Application No.: 10/648,811

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter, J.D., Ph.D.

Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458 Alameda, CA 94501 (510) 337-7871

Fax (510) 337-7877

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	omplete if Known		
	Application Number	10/648,811	1. 1. 1. 1.
INFORMATION DISCLOSURE	Filing Date	August 25, 2003	/s, -
STATEMENT BY APPLICANT	First Named Inventor	Paul A. Price	2
	Group Art Unit	Unassigned	MAR 0 7 2003 0
	Examiner Name	Unassigned	1.9
(use as many sheets as necessary)	Attorney Docket Number	407T-895413US	VER JOH
	Date Submitted	March 4, 2005	MANTANTANA

Examiner Cite No.		Kind Code (if known)	Cited Document	Cited Document	Where Relevant Passages
1	4 000 007	1	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
	4,628,027		Gay	12/9/1986	
2	4,782,017		Serban et al.	11/1/1988	
3	5,726,061		Robbins et al	3/10/1998	
4	5,773,259		Kirkpatrick	6/30/1998	

		FOREIGN Foreign Patent Document				Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	L
	5	wo	93/22429			1993		
	6	wo	95/01995	·		1995		
	7	JP	63023898A			1988		
	8	EP	0805206 A			1997		
	9	wo	9806859A			1998		
	10	EP	0398753			1990		
	11	wo	90/08195			1990		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	12	Been et al. (1986) Cell 47:207-216	
	13	Campbell (1991) Biochemistry and Molecular Biology 23:1-114	
	14	Gillies et al. (1989) Bio/Technology 7:799-805	
	15	Gorman et al. (1982) Proc. Natl. Acad. Sci. 79: 6777-6781	
•	16	Hakala et al. (1993) J. Biol. Chem. 268 (34): 25803-25810	
	17	Orslev-Petersen et al. (1986) Arthritis and Rheumatism 29 (5) 592-599	
	18	Horslev-Petersen et al. (1988) Clin. & Exp. Rheumatology 6: 129-134	

Examiner	Date	Э
Signature	Con	sidered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	C	omplete if Known
	Application Number	10/648,811
INFORMATION DISCLOSURE	Filing Date	August 25, 2003
STATEMENT BY APPLICANT	First Named Inventor	Paul A. Price
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
(use as many sheets as necessary)	Attorney Docket Number	407T-895413US
	Date Submitted	March 4, 2005

19	Hu et al. (1996) J. Biol. Chem. 271 (32) 19415-19420
20	Isselbacher et al. (1976) Harrison's Principles of Internal Medicine 1865-1867, 1870-1879, 1894-1896
21	Johansen et al. (1992) J. Bone and Mineral Res. 7 (5): 501-512
22	Johansen et al. (1992) Abstract for Scientific Conference published on or after July 12, 1992
23	Johansen et al. (1993) Br. J. Rheumatology 32 (11): 949-955
24	Krieg et al. (1984) Nucleic Acids Res. 12 (18):7057-7071
25	MacNaul et al. (1990) J. Biol. Chem. 265 (28): 17238-17245
26	Mauer et al. (1980) Meth. Enzymol. 70:49-70
27	Norton et al. (1985) Mol. And Cellular Biol. 5(2): 281-290
28	Nyirkos et al. (1990) Biochem. J. 268:265-268
29	Raz et al. (1993) Proc. Nat Acad Sci. 90 (10) 4523-4527
 30	Rejman et al. (1988) Biochem. Biophys Res. Comm. 150: (1) 329-334
31	Renkema et al. (1995) J. Biol. Chem 270 (5) 2198-2202
32	Rhode et al. (1979) Eur. J. Clin. Investigation 9: 451-459
 33	Salacinski et al. (1981) Anal. Biochem 117:136-146
 34	Saxne et al. (Annal. Rheumatic Dis. 45: 491-497
 35	Thomas (1988) Tabers Cyclopedic Medical Dictionary 372-373
36	Ulmer et al. (1992) Science 259: 1745-1749
 37	Ward et al. (1989) Nature 341:544-546
 38	Grossman et al. (1996)EMHUM2 Database Accession No. HSU58514
39	Grossman et al. (1996) EMHUM2 Database Accession No. HSU58515
 40	(1996) EMHUM2 Database Accession No. HSU49835
41	(1996) TRHUM Database Accession No. Q15749, A15782 and Q15783

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.